Results 71 to 80 of about 656,371 (370)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Current Practice and Future Directions

Cancers, 2021
Simple Summary Acute lymphoblastic leukemia minimal residual disease (MRD) refers to the presence of residual leukemia cells following the achievement of complete remission, but below the limit of detection using conventional morphologic assessment.
G. P. Contreras Yametti, Talia H Ostrow, S. Jasinski, E. Raetz, W. Carroll, Nikki A. Evensen   +5 more
semanticscholar   +1 more source

Molecular Dynamics Studies of Dog Prion Protein Wild-type and Its D159N Mutant [PDF]

Journal of Biomolecular Structure and Dynamics 2021 Volume 39, Issue 12, Pages 4234-4242, 2017
Prion diseases (e.g. "mad cow" disease in cattle, chronic wasting disease in deer and elk, CJD in humans) have been a major public health concern affecting humans and almost all animals. However, dogs are strongly resistant to prion diseases. Recently, it was reported that the single (surface) residue D159 is sufficient to confer protection against ...
arxiv   +1 more source

Comparison between qualitative and real-time polymerase chain reaction to evaluate minimal residual disease in children with acute lymphoblastic leukemia

Revista Brasileira de Hematologia e Hemoterapia, 2015
Introduction: Minimal residual disease is an important independent prognostic factor that can identify poor responders among patients with acute lymphoblastic leukemia.
Francisco Danilo Ferreira Paula, Silvana Maria Elói-Santos, Sandra Guerra Xavier, Mônica Aparecida Ganazza, Patricia Yoshioka Jotta, José Andrés Yunes, Marcos Borato Viana, Juliana Godoy Assumpção   +7 more
doaj   +1 more source

Minimal residual disease in breast cancer: in blood veritas. [PDF]

, 2014
A blood-based molecular test might direct recommendations for systemic therapies in patients with early-stage breast cancer undergoing surgery with curative intent.
Bardelli, Alberto, Siravegna, Giulia
core   +1 more source

Residual inflammation in psoriatic arthritis patients in stable minimal disease activity [PDF]

, 2022
Background: In psoriatic arthritis (PsA), low disease activity as defined by the Minimal Disease Activity (MDA) index is considered a good treatment target.
Bruschi M., Ciancio G., Focherini M., Govoni M., Macchioni P., Malavolta N., Marchesoni A., Mascella F., Montaguti L., Salvarani C., Sandri G., Spinella A., Vukatana G., Zabotti A., Zuliani F.   +14 more
core   +1 more source

Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia

FEBS Letters, EarlyView.
This Review explores how the phosphoinositide 3‐kinase and protein kinase B pathway shapes B cell development and drives chronic lymphocytic leukemia, a common blood cancer. It examines how signaling levels affect disease progression, addresses treatment challenges, and introduces novel experimental strategies to improve therapies and patient outcomes.
Maike Buchner
wiley   +1 more source

Ablation of LRP6 in alpha‐smooth muscle actin‐expressing cells abrogates lung inflammation and fibrosis upon bleomycin‐induced lung injury

FEBS Letters, EarlyView.
Low‐density lipoprotein receptor‐related protein 6 (LRP6) is a key receptor for the Wnt antagonist Dickkopf1 (DKK1). DKK1 protein expression is induced in a bleomycin (BLM)‐induced lung injury model. We show that DKK1 induces proinflammatory and profibrotic genes in lung fibroblasts.
Eun‐Ah Sung, Mikhail G. Dozmorov, SuJeong Song, Theingi Aung, Min Hee Park, Patricia J. Sime, Wook‐Jin Chae   +6 more
wiley   +1 more source

Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia

Revista Brasileira de Hematologia e Hemoterapia, 2015
Minimal residual disease is the most powerful predictor of outcome in acute leukemia and is useful in therapeutic stratification for acute lymphoblastic leukemia protocols. Nowadays, the most reliable methods for studying minimal residual disease in acute
Maura Rosane Valério Ikoma, Miriam Perlingeiro Beltrame, Silvia Inês Alejandra Cordoba Pires Ferreira, Elizabeth Xisto Souto, Mariester Malvezzi, Mihoko Yamamoto   +5 more
doaj   +1 more source

Roadmap to cure multiple myeloma [PDF]

, 2021
Despite significant advances in the treatment of multiple myeloma which had led to unprecedented rates of response and survival, patients still relapse, and cure remains elusive.
Paiva, B. (Bruno), Rodriguez-Otero, P. (Paula), San-Miguel, J.F. (Jesús F.)   +2 more
core  

Making tau amyloid models in vitro: a crucial and underestimated challenge

FEBS Letters, EarlyView.
This review highlights the challenges of producing in vitro amyloid assemblies of the tau protein. We review how accurately the existing protocols mimic tau deposits found in the brain of patients affected with tauopathies. We discuss the important properties that should be considered when forming amyloids and the benchmarks that should be used to ...
Julien Broc, Clara Piersson, Yann Fichou
wiley   +1 more source